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Abstract
Treatments for women with recurrent brain metastases from breast cancer are limited. In this
phase II study, we administered sagopilone to patients with breast cancer and brain metastases.
We observed modest activity with a central nervous system objective response rate of 13.3%;
however, median PFS was disappointing. Further studies should focus on other agents to treat this
challenging clinical problem.
Background—Patients with progressive metastatic breast cancer to the central nervous system
(CNS) have limited treatment options.
Patients and Methods—We conducted a phase II study of sagopilone, an epothilone B
analogue that crosses the blood-brain barrier, in patients with breast cancer brain metastases.
Women were treated with 16 mg/m2 or 22 mg/m2 intravenously every 21 days. The primary
endpoint was CNS objective response rate (ORR). Secondary endpoints included toxicity,
progression-free survival (PFS), and overall survival (OS). Using modified, high-resolution
magnetic resonance angiography (MRA), we also evaluated changes in vessel tortuosity with
treatment.
Results—Fifteen women were enrolled; all had progressive CNS disease despite whole-brain
radiotherapy. Two patients achieved a partial response (ORR, 13.3%) and remained in the study
for 6 cycles. Responses were not associated with normalization of tumor-associated vessels on
correlative imaging studies. Median PFS and OS were 1.4 months and 5.3 months, respectively.
The most common grade 3 toxicities were lymphopenia and fatigue. Enrollment was stopped
prematurely because of limited observed activity and slow accrual.
Conclusions—Sagopilone was associated with modest CNS activity in patients with breast
cancer; however median PFS was disappointing. Further studies should examine other potentially
active agents and/or combinations for this challenging clinical problem.
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Introduction
Approximately 10% to 15% of women with metastatic breast cancer will experience brain
metastases.1-6 Patients with human epidermal growth factor receptor 2–positive (HER2+) or
triple-negative breast cancer have a particularly high risk of central nervous system (CNS)
involvement.6-10 Few prospective trials have evaluated the role of systemic therapies for the
treatment of brain metastases from breast cancer.11-14 Consequently there is no consensus
on appropriate treatment for women in whom CNS progression develops after first-line
CNS-directed therapy with whole-brain radiation therapy (WBRT), stereotactic radiosurgery
(SRS), surgical resection, or a combination of modalities.
Epothilones are a new class of tubulin-stabilizing agents that have demonstrated responses
in taxane-naive and pretreated breast cancer patients with systemic metastases.15-18
Sagopilone (ZK-Epothilone, ZK 219477, ZK-EPO), is an epothilone B analogue with
activity in multidrug resistant (MDR)-displaying, taxane-resistant cell lines.19-21 Sagopilone
is not a substrate of P-glycoprotein and readily crosses the blood-brain barrier.22,23
Furthermore, initial studies with sagopilone in patients with recurrent glioma demonstrated
promising clinical activity.24,25 Although several phase I20,26,27 and phase II24,28 studies
with sagopilone have been completed in multiple solid tumor settings, no studies have
examined this agent's efficacy in breast cancer metastatic to the CNS.
We conducted a 2-stage phase II single-arm study to evaluate the clinical efficacy and
toxicity profile of sagopilone in women with breast cancer and CNS metastases. Because of
sagopilone's ability to cross the blood-brain barrier and evidence of systemic activity in
treatment-refractory settings, we hypothesized that this agent would be active in patients
with brain metastases. We report the findings from our study here.
Patients and Methods
Study Cohort: Eligibility
Adult patients aged ≥ 18 years with histologically confirmed invasive breast cancer and
progressive measurable CNS disease (defined as ≥ 1 lesion ≥ 10 mm in longest dimension)
were eligible. Previous CNS-directed therapy for brain metastases was required and could
include surgery, WBRT, SRS, or a combination of therapies. Patients with progressive or
new CNS lesions after CNS-directed therapy were eligible. Patients with multiple CNS
lesions, 1 or several of which were previously treated with SRS or surgery, were eligible
provided that they had ≥ 1 residual untreated measurable lesion. Other inclusion criteria
included a lack of increase in corticosteroid use during the week before baseline imaging,
Eastern Cooperative Oncology Group (ECOG) performance status 0-2, and adequate bone
marrow and end-organ function.
Patients were excluded if they had received chemotherapy within 3 weeks of study entry.
Concurrent receipt of other investigational agents or cancer-directed therapy was not
allowed, with the exception of ovarian suppression (when used for > 6 months, during which
time CNS disease progression was documented) and bisphosphonates. Patients were
excluded if they received previous treatment with investigational chemotherapy for brain
metastases, a previous epothilone, or concurrent enzyme-inducing antiepileptic drugs. Those
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with grade 2 or higher peripheral neuropathy, leptomeningeal disease as the only site of
CNS disease, or > 2 seizures during the month before study entry were not eligible.
This study was conducted in accordance with established guidelines as recommended by the
US Department of Health and Human Services and was approved by the Institutional
Review Board at Dana-Farber Cancer Institute/Harvard Cancer Center (Boston, MA).
Treatment Plan and Stopping Rules
In this 2-stage phase II single-arm study, the first patient cohort received a starting dose of
sagopilone at 16 mg/m2 intravenously every 21 days. In August 2008, after 9 patients had
been enrolled, the protocol was amended to evaluate sagopilone at 22 mg/m2 based on
preliminary data from other breast cancer studies that the higher dose may be more
efficacious (Lars Breimer, personal communication). The second cohort therefore had a
starting dose of sagopilone 22 mg/m2 every 21 days. This protocol had early stopping rules
for both toxicity (≥ 3 patients [among the first 8] enrolled at 16 mg/m2 having grade 3/4
CNS toxicity, ≥ 3 patients enrolled at 22 mg/m2 withdrawing from the study before the first
restaging because of toxicity) and for objective response (no responses in the first 12
patients on the 16 mg/m2 dose). If these stopping rules were not invoked, a total of 37
patients were to receive the 22 mg/m2 dose. If 4 of these 37 patients had an objective
response, sagopilone would be considered worthy of further study.
At baseline and every 2 cycles, patients underwent brain magnetic resonance imaging (MRI)
and computed tomography of the chest, abdomen, and pelvis. In addition, at baseline and at
6 weeks correlative imaging was obtained using modified high-resolution magnetic
resonance angiography (MRA). Adverse events were captured at each visit. Tumor-
associated neurologic signs and symptoms, corticosteroid use, and drug-related neurologic
toxicities were documented each cycle using a worksheet designed for this study. Patients
were continued on therapy until disease progression (CNS, systemic, or both), intercurrent
illness that prevented therapy administration, unacceptable adverse events, or patient/
provider decision for withdrawal.
Response Definitions and Statistical Analyses
The primary efficacy endpoint was objective response rate (ORR, defined as complete
response [CR] plus partial response [PR]) in the CNS. CNS responses were defined as
follows: (1) CR, disappearance of all target and nontarget lesions; (2) PR, ≥ 50% decrease in
the sum of volume of up to 5 target lesions, taking as reference the baseline sum volume; (3)
progressive disease (PD), ≥ 40% increase in the sum of the volume of target lesions (relative
to the smallest sum recorded since treatment started) or the appearance of ≥ 1 new lesions;
and (4) stable disease (SD), neither sufficient shrinkage nor increase to qualify for PRor PD.
Evaluation of all CNS imaging was performed centrally at the Tumor Imaging Metrics Core
(TIMC) of Dana-Farber/Harvard Cancer Center, as described previously.13 In non–CNS
sites, responses were evaluated by individual site personnel (without central review)
according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0.29
Secondary objectives included determination of safety and tolerability, ORR in non–CNS
sites, clinical benefit rate (CR, PR, or SD in the CNS ≥ 24 weeks with at least concurrent SD
in non–CNS sites), first site of treatment failure, PFS, and OS. PFS and OS were analyzed
using Kaplan-Meier product limit methods and the remaining secondary outcomes were
summarized with descriptive statistics.
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Previous studies have suggested that CNS vessel tortuosity is provoked by malignancy and
that normalization of vessels is associated with treatment response, even to agents without
intrinsic antiangiogenic activity.30-33 We therefore incorporated novel exploratory imaging
analyses at baseline and at 6 weeks to characterize vessel density and tortuosity and to
calculate the malignancy probability (MP) score using modified, high-resolution MRA,
using methods previously described by Bullitt et al and Parikh et al; MP scores > 50 have
been associated with malignancy.30-34
Results
Patient Characteristics
A total of 15 women were enrolled from August 1, 2007 to October 29, 2009 (9 patients at
16 mg/m2 ; 6 patients at 22 mg/m2). Enrollment was terminated prematurely because of a
combination of review of preliminary efficacy data and slow accrual. Baseline
characteristics are shown in Table 1. The median age was 51 years (range, 31-74 years).
Sixty percent of patients had a baseline ECOG performance status of 1. Eleven patients had
HER2+ tumors; only 1 patient had triple-negative disease. Approximately half of patients
had received ≥ 3 lines of chemotherapy for metastatic disease. All 15 patients had received
previous WBRT; other previous CNS-directed treatments included surgery (n = 2) and SRS
(n = 11).
Efficacy
The primary endpoint was CNS ORR. Of 15 patients, 2 achieved a PR (ORR, 13.3%), 1 at
each dose level (Table 2); 1 patient had estrogen receptor (ER) /HER2 disease and the other
patient had ER+/HER2– disease. Both of these patients remained in the study for 6 cycles
before withdrawing for CNS progression. Selected brain MRI images from the partial
responders are shown in Figure 1. No minor responses were observed. Notably, 10/15
patients withdrew from the study after only 2 cycles, 8 because of CNS progression, with a
median duration in the study of 2 cycles (range, 1-6). Overall, reasons for withdrawing from
the study were CNS progression (n = 12), toxicity (n = 1), physician/patient withdrawal for
clinical progression (n = 1), and death (n = 1).
Results of analyses for secondary endpoints included ORR in non–CNS sites (0%), clinical
benefit rate (13.3%), and 6-month PFS (0%). Median PFS and OS were 1.4 months and 5.3
months, respectively. Three patients remained alive at last known follow-up. Of note,
confidence intervals could not be calculated for ORR, OS, and PFS because of stopping
rules based on number of responses or on number of patients completing 2 cycles of therapy,
and also because neither dose cohort completed the planned accrual to the first stage.
Toxicity
Both dosing levels were generally well tolerated (Table 3), although 1 patient who received
22 mg/m2 experienced grade 4 transaminitis and grade 5 pulmonary embolus (PE) during
the first cycle of therapy. The PE resulted in death from respiratory failure within 12 hours
of emergency room presentation. Another patient withdrew from the study for unacceptable
toxicity related to hydrocephalus; however this patient died of clinical progression shortly
thereafter and the event was ultimately felt to be unrelated to therapy. Grade 3 adverse
events were relatively uncommon at both dosing levels but were observed with higher
frequency at the 22 mg/m2 dose. These events included fatigue (n = 3), lymphopenia (n = 3),
leukopenia (n = 2), muscle/joint aches, neuropathy, ataxia, dizziness, neutropenia, and
weakness (1 patient each). Of note, the neuropathy and ataxia occurred in patients who
received 1 to 2 cycles of therapy before clinical progression. Overall, 2 patients required
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dose reductions from 22 mg/m2 to 16 mg/m2 and 1 of these patients required an additional
dose reduction to 12 mg/m2.
Correlative Imaging Studies
Of 15 patients who had baseline imaging, 10 had markedly abnormal intracranial vessel
tortuosity (mean MP score, 99.2; range, 90-100). Of 10 evaluable patients with paired,
posttreatment images at 6 weeks, all had persistently abnormal vasculature (MP score range,
99-100; maximum change in score from baseline = 1 point). Other measures of vessel
tortuosity (ie, sum of angles metric and inflection count metric) also demonstrated high
levels of tortuosity for all evaluable patients (data not shown). Of note, the 2 patients with
volumetric decreases in target lesions both had persistently and highly abnormal tortuosity
values (MP score,100 at both time points for both patients). Example images illustrating the
observed vessel tortuosity in 1 patient are shown in Figure 2.
Neurologic Signs and Symptoms
Neurologic examination worksheets were completed by providers at baseline and at each
visit; they evaluated patients for several domains: level of consciousness (LOC), symptoms
(ie, headaches, nausea), cranial nerve deficits, language, sensation, ataxia, overall neurologic
status (improved, stable, worsening), and potential attributions to therapy. At baseline all
patients were reported to have a normal LOC; new somnolence was recorded in 2 patients at
progression. Headaches, dizziness, and vertigo were infrequent and were generally mild to
moderate with the exception of 1 patient who had severe dizziness at progression (felt to be
related to therapy). Two patients had moderate ataxia and 5 patients had mild ataxia
attributed to disease progression; 1 patient could not be assessed for ataxia because of
bedridden status from disease progression. It is of note that ataxia was more commonly
reported on the worksheets than on toxicity assessments from medical record review.
With regard to findings from the neurologic worksheets for the 2 responders, 1 partial
responder remained asymptomatic until progression; the second responder had begun
sagopilone while on a stable dose of dexamethasone (4 mg daily). These steroids were
discontinued by the start of cycle 2 but were then restarted at progression. Other neurologic
signs and symptoms were stable while these patients were receiving therapy. Changes in
overall neurologic symptoms and signs for all women in the study are shown in Table 4.
Overall worsening neurologic status was noted in 9 patients at progression; 7 of these
patients also had clinical worsening in ≥ 1 domain (included ataxia in all 7 patients). Five
patients had overall worsening neurologic signs and symptoms that were felt to be at least
partially attributed to sagopilone. These observations are somewhat challenging to interpret
because of concurrent disease progression.
Premature Trial Closure
Over the course of our study several concerns arose, which resulted in a decision to close the
protocol after 15 patients had enrolled (reaching the time when stopping rules could be
assessed). Emerging data from other ongoing studies showed that the activity of sagopilone
was less than expected among breast cancer patients in general.35 In addition, these 15
patients experienced moderate toxicity, and a majority of patients had rapid progression
while in the study. Because of these issues as well as slow accrual, we felt that continuation
of the study as planned was not an appropriate use of patient resources.
Discussion
In this phase II study we evaluated the efficacy and toxicity profile of sagopilone in patients
with breast cancer and progressive brain metastases. We observed a CNS ORR of 13.3%
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with a median PFS of 1.4 months and median OS of 5.3 months. Two thirds of patients
withdrew from the study after the first restaging evaluation, mostly for progressive CNS
disease, and most patients had worsening neurologic status at the time of progression.
Sagopilone toxicities were largely manageable. The most common grade 3 toxicities were
lymphopenia and fatigue. In a previous phase I study with this agent (306821) (Sagopilone
[ZK-EPO, ZK219477] Investigator's Brochure, Version 6.0, November 28, 2007, Bayer
Schering Pharma AG), 2 cases of ataxia of CNS origin were observed, 1 at the 22 mg/m2
dose and 1 at the 29 mg/m2 dose, raising concerns about the safety profile of sagopilone
(Investigator Brochure). Reassuringly we did not observe any definite cases of central ataxia
that were clearly attributable to therapy.
The advent of novel therapies has been associated with prolongation of survival for some
women with CNS metastases,36,37 likely as a result of better systemic disease control. Our
trial may be representative of these outcomes, as the median time from diagnosis of CNS
metastasis to study entry was 25 months (range, 6-52 months). Furthermore nearly all
patients withdrew from the study for CNS (as opposed to systemic) progression and 3 (20%)
patients remained alive at 1.5 to 2.5 years after study registration. Investigation of CNS-
directed therapies will become increasingly important as a number of these long-term
survivors have the brain as their dominant site of disease progression.
Although preclinical studies demonstrated sagopilone's ability to cross the blood-brain
barrier,23 results of clinical trials with this drug were somewhat disappointing. This may
have occurred for several reasons. When we initiated this study, preliminary evidence of
antitumor activity had been observed across multiple early-phase trials of sagopilone in solid
tumors, including breast cancer. In addition, prolonged responses were observed in
glioblastoma multiforme (GBM).24 Since then a subsequent phase II trial of sagopilone in
38 patients with recurrent GBM demonstrated no objective disease responses, and the
authors concluded that sagopilone was not worthy of future study for this indication.38
Furthermore in a study of 65 women with refractory metastatic breast cancer without
symptomatic CNS involvement, the ORRfor 2 dosing levels was 4.6% and the median
number of cycles delivered was 2.35
These evolving data have demonstrated that sagopilone may simply not be an adequately
effective agent to treat breast cancer, as suggested by the low systemic response rates in
women with metastatic disease outside the CNS. Results of these trials also contributed to
our decision to close the current study before full accrual. However other epothilones are
still under study in women with breast cancer metastatic to the brain. For example in a
preliminary report of 38 evaluable women with progressive brain metastases who received
patupilone, a natural epothilone B, the 3-month PFS was 37% and the median CNS PFS was
57 days. Five (13%) women experienced PR in the CNS and 12 women (32%) had SD,
meeting patupilone's prespecified threshold for further investigation.39 In our study,
although the 2 responders remained in the study for 6 cycles, no additional patients achieved
SD > 12 weeks.
Because the majority of patients enrolled in this study had HER2+ disease, it is conceivable
that we would have observed more frequent and/or more durable responses with sagopilone
if administered in combination with a HER2-targeted agent. For example the addition of
lapatinib to capecitabine in patients with HER2+ metastatic breast cancer was associated
with improvements in ORR and PFS in addition to a nonsignificant decrease in CNS
events.40 Because of the limited observed activity of sagopilone in women with metastatic
breast cancer (with and without CNS disease), further study of sagopilone in this patient
population will not likely not be pursued.
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Our study had several limitations. This was a small single-center study of heavily pretreated
patients. It is possible that we would have observed more activity in patients who had
received less chemotherapy exposure previously; however such patients are also less likely
to have refractory brain metastases, which was the subject of our trial. All patients with
measurable metastatic CNS disease were eligible for this trial irrespective of tumor subtype,
which may have limited our ability to detect a benefit in a specific subset of breast cancer
patients. However the 2 women who experienced PRs had ER+/HER2– and ER+/HER2+
primary breast cancers, which does not suggest a clear trend for activity in a particular
subtype. Only 1 patient in our study had triple-negative disease (and had disease progression
at first re-staging). Although it is possible that a clinical benefit was missed by prematurely
closing our trial after enrollment of 15 patients, in the context of emerging data of this agent
in systemic metastatic breast cancer, we feel that our decision was justified. Although we
did not include formal neurocognitive testing as a measure of clinical benefit, we found that
the neurologic signs and symptoms worksheet was sensitive to change, as most patients
experienced worsening symptoms (ie, ataxia) at progression. Finally with respect to the
correlative imaging, we cannot rule out the possibility that significant vessel changes (in
responders) may have occurred beyond 6 weeks; whether vessel changes are a true marker
of clinical benefit of sagopilone is unknown.
The results of our study have demonstrated limited clinical activity of sagopilone in patients
with breast cancer metastatic to the brain. Further study of sagopilone as a single agent in
this patient population is not currently warranted. We cannot rule out the possibility that
responses in HER2+ patients may have been more frequent and/or more durable with
concurrent HER2-directed therapy; however there may be more attractive chemotherapy
partners. Future investigations of novel regimens for women with brain metastases are
urgently needed and should be a priority for research.
Conclusion
Patients with progressive brain metastases from breast cancer have limited treatment
options. Few prospective trials have evaluated the role of systemic therapies for this
challenging clinical situation, and consequently there is no consensus on appropriate
treatment for women who experience progression after first-line CNS-directed therapy. In
addition to preclinical data demonstrating sagopilone's ability to cross the blood-brain
barrier, preliminary reports suggested promising systemic activity of sagopilone for patients
with stage IV breast cancer and for those with GBM. These preliminary data provided the
rationale for our study design.
We conducted a phase II study of sagopilone, an epothilone B analogue, in patients with
breast cancer brain metastases that progressed after receipt of first-line CNS-directed
therapy. Women received sagopilone at 16 mg/m or 22 mg/m2 intravenously every 21 days.
Our primary endpoint was CNS ORR, and secondary end-points included toxicity, PFS, and
OS. Using modified high-resolution MRA, we also evaluated changes in vessel tortuosity
with treatment. Among the 15 women enrolled in the study, 2 patients achieved a PR (ORR
13.3%) and remained in the study for 6 cycles. Responses were not associated with
normalization of tumor-associated vessels on correlative imaging studies. Median PFS and
OS were 1.4 months and 5.3 months, respectively, and the most common grade 3 toxicities
were lymphopenia and fatigue. Enrollment was stopped prematurely because of limited
observed activity, evolving data regarding the lack of activity in metastatic breast cancer and
glioblastoma, and slow accrual.
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The results of our study were disappointing and further study of sagopilone as a single agent
in this patient population is not currently warranted. Future investigations of novel regimens
for women with brain metastases are urgently needed and should be a priority for research.
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• Management of breast cancer that has metastasized to the brain is a challenging
clinical problem, particularly for those patients who experience recurrent CNS
disease.
• Current treatment options for these patients may include repeated stereotactic
surgery, whole brain radiation therapy, craniotomy, systemic therapy, or
enrollment on a clinical trial.
• The results of our phase II protocol of sagopilone in women with breast cancer
and progressive brain metastases suggest minimal and short-lived activity of this
agent with regard to central nervous system response.
• Further study of sagopilone as a single agent in this setting is not currently
warranted. Future investigations of novel treatments for this clinical problem are
urgently needed and should be a priority for research.
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Selected Images for Partial Responders. (A) Comparable Axial T1-GAD Slices at Times 1
and 2 in Patient 5 With Multiple Lesions. Arrows Point to 2 Large Peripheral and a Third
Small Midline Lesion at Time 1. At Time 2, All 3 Lesions Reduced Dramatically in Volume
as Illustrated Here in the 2-Dimensional Slice Data; (B) Comparable Axial T1-GAD Slices
at Times 1 and 2 in Patient 11 With Multiple Lesions. Arrows Point to 2 Left Cerebellar and
a Faint Right Cerebellar Lesion. At Time 2, All 3 Lesions Reduced Dramatically in Volume
as Illustrated Here in the 2-Dimensional Slice Data
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Images of 3-Dimensional Segmented Vessels From a Patient in the Study. Connected Vessel
Groups Have Been Color-Coded for Easier Identification. Cyan = Left Middle Cerebral
Group, Blue = Right Middle Cerebral Group, Red = Anterior Cerebral Group, Gold =
Posterior Cerebral Group. (A) AP View; (B) Base View; (C) Lateral View. White Boxes
Indicate Regions Enlarged in D and E. (D and E) Magnifications of Part of the Posterior
Circulation Shown in C to Illustrate the Abnormal Vessel Tortuosity Associated With
Cancer
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Table 1
Patient Characteristics (N = 15)
Characteristic No. of Patients (%)
Age, Years
 Median 51 years
 Range 31-74 years
White Race 15 (100)
Female Gender 15 (100)
ECOG Performance Status
 0 2 (13)
 1 9 (60)
 2 4 (27)
Stage at Initial Diagnosis
 I 5 (33)
 II 5 (33)
 III 1 (7)
 IV 4 (27)
Primary Tumor Receptor Status
 ER+,HER2– 3 (20)
 ER+,HER2+a 7 (47)
 ER–, HER2+a 4 (27)
 Triple negative 1 (7)
Adjuvant Chemotherapy Received
 Anthracycline 3 (20)
 Anthracycline and taxane 4 (27)
 Nonanthracycline, nontaxane 0 (0)
 Trastuzumab-inclusive 2 (13)
 None 4 (27)
 Not Applicableb 4 (27)




 CNS 15 (100)
 Lung or pleura 6 (40)
 Liver 7 (47)
 Bone 10 (67)
 Breast or chest wall 0 (0)
 Other sites 4 (27)
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Characteristic No. of Patients (%)
Number of Previous Chemotherapy Regimens (for Metastases Only)
 0 2 (13)
 1 4 (27)
 2 2 (13)
 ≥3 7 (47)
Systemic Therapy Exposure (for Metastases Only)
 Taxane 9 (60)
 Capecitabine 11 (73)
 Trastuzumab or lapatinib 9 (60)
 Vinorelbine 7 (47)
 Carboplatin 3 (20)
 Temozolomide 1 (7)
 Hormonal therapy 7 (47)
 Antiangiogenic therapy 0 (0)
 Anthracycline 1 (7)
Previous Treatment of CNS Disease
 CNS surgery 2 (15)
 SRS brain only 0 (0)
 WBRT 15 (100)
 SRS and WBRT 11 (73)
Abbreviations: CNS = central nervous system; ECOG = Eastern Cooperative Oncology Group; ER = estrogen receptor; HER2 = human epidermal
growth factor receptor 2; SRS = stereotactic radiosurgery; WBRT = whole brain radiotherapy.
a
HER2+ = deemed positive by immunohistochemistry or fluorescence in situ hybridization.
b
Initial diagnosis was stage IV disease.
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Table 2
Overall CNS Activity Rate for Sagopilone (N = 15)
Response Number of Patients (%)a
Overall Response 2 (13)
Complete Response 0 (0)
Partial Response 2 (13)
Stable Disease (> 12 Weeks) 0 (0)
Clinical Benefit Rateb 2 (13)
6-Month PFS 0 (0)
Abbreviation: PFS = progression-free survival.
a
Note: Confidence intervals could not be calculated because of the different stopping rules and because neither dose cohort completed the planned
accrual to the first stage.
b
Defined as complete response, partial response, or stable disease ≥ 24 weeks in the central nervous system, with at least concurrent stable disease
in non–central nervous system sites.
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Table 4
Changes in Neurologic Signs and Symptoms for Women Receiving Sagopilone (N = 15)a
Study Time Point
Overall Status of Neurologic Signs and Symptoms (n)
Worsening of ≥1 Neurologic Domainb
Improved Stable Worsening
Midtherapy 1 8 2c 7 (of 11)
Progression/withdrew from study 0 5 9c 10 (of 14)d
a
Three patients had progression at second assessment and did not have “midtherapy” evaluations; 1 patient did not have assessments beyond
baseline.
b
Domains included level of consciousness, symptoms, cranial nerves, language, strength, sensation, and ataxia.
c
At midtherapy and progression in 1 woman and 5 women, respectively, the signs and symptoms were felt to be possibly, probably, or definitely
related to therapy.
d
Seven of these patients had worsening overall status.
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